Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India
Background and Objectives: Vaccination being the only way to reduce mortality from the dreaded COVID-19 disease, the vaccine was introduced in India as per the advice of the National Expert Group on January 16, 2021. Duration of immune response elicited by the vaccines has always been a matter of content. With new variants emerging every other day, the study was done to look for the antibody response in vaccine recipients post second dose of vaccination.
Materials and Methods: A longitudinal observational study was conducted from August 2021 to February 2022 in fully vaccinated individuals who took either Covishield (AZD1222) or Covaxin (BBV-152). Blood was collected from the individuals at 12-16 weeks post-vaccination to look for IgG antibody response against S1 spike protein of SARS-CoV2 by ELISA. Follow-up was done at 32 weeks post the second dose in individuals who had received Covishield.
Results: Among 176 individuals, IgG antibody against S1 spike protein was found to be positive in 89.7% (158). Covishield recipients showed higher antibody response (99.1%) as compared to Covaxin recipients (71%). Antibody response was higher in males, individuals less than 50 years, and non-comorbid individuals. Of 38 Covishield recipients, IgG antibody response was positive in 28 (73.6%) individuals when followed up at 32 weeks post the second vaccination dose.
Conclusion: The study gives us input with regard to the long-term antibody kinetics of both vaccines. The study has a follow-up plan to co-relate the antibody response to the neutralization test.
2. Interim report on WHO’s response to COVID - January - April 2020. Date accessed: December 2021 https://www.who.int/publications/m/item/interim-report-on-who-s-response-to-covid---january---april-2020
3. Press Statement by The Drugs Controller General of India (DCGI) On Restricted Emergency Approval of Covid-19 Virus Vaccine. Press Information Bureau, New Delhi, India; 2021. Date accessed: Jan 2022 https://www.icmr.gov.in/pdf/press_realease_files/HFW_DCGI_energency_use_authorisation_03012021_2.pdf
4. Kumar VM, Pandi-Perumal SR, Trakht I, Thyagarajan SP. Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. NPJ Vaccines 2021; 6: 60.
5. MoHFW. Revised Guidelines for implementation of National COVID Vaccination Program. 2021. Date accessed: Oct 2021. https://www.mohfw.gov.in/pdf/RevisedVaccinationGuidelines.pdf
6. Altawalah H. Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines (Basel) 2021; 9: 910.
7. Singh AK, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A, et al. Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine 2021; 39: 6492-6509.
8. Choudhary HR, Parai D, Chandra Dash G, Kshatri JS, Mishra N, Choudhary PK, et al. Persistence of antibodies against spike glycoprotein of SARS CoV 2 in healthcare workers post double dose of BBV-152 and AZD1222 vaccines. Front Med (Lausanne) 2021; 8: 778129.
9. Muller L, Andree M, Moskorz W, Drexler I, Walotka L, Grothmann R, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 Coronavirus disease 2019 vaccination. Clin Infect Dis 2021; 73: 2065-2072.
10. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY) 2020; 12: 9959-9981.
11. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529): eabf4063.
12. Vanshylla K, Di Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L, et al. Kinetics and correlates of the neutralizing antibody response to SARSCoV-2 infection in humans. Cell Host Microbe 2021; 29: 917-929.e4.
13. Anderson M, Stec M, Rewane A, Landay A, Cloherty G, Moy J. SARS-CoV-2 antibody responses in infection-naive or previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine. JAMA Netw Open 2021; 4(8): e2119741.
14. CDC. COVID‐19 Vaccine Effectiveness Research 2021. Date accessed: April 12, 2021, www.cdc.gov/vaccines/covid-19/effectiveness-research/protocols.html
15. Dash GC, Subhadra S, Turuk J, Parai D, Rath S, Sabat J, et al. Breakthrough SARS‐CoV‐2 infections among BBV‐152 (COVAXIN®) and AZD1222 (COVISHIELDTM) recipients: Report from the eastern state of India. J Med Virol 2022; 94: 1201-1205.
16. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates of antibody positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet 2021; 397: 1459-1469.
17. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162B2 Covid 19 vaccine over 6 months. N Engl J Med 2021; 385(24): e84.
18. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020; 396: 1595-1606.
19. Dolgin E. COVID vaccine immunity is waning - how much does that matter? Nature 2021; 597: 606-607.
|Issue||Vol 14 No 5 (2022)|
|Immunoglobulin G; Vaccination; India; Spike glycoprotein|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|